Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.
- Rina M. Mbofung
- Jodi A. McKenzie
- Patrick Hwu
